Unlike cases of AML, where IDH-2 and TET-2 mutations are mutually exclusive and associated with adverse prognosis, in AITL they are usually seen concurrently, which suggests a cooperative effect between both mutations for expansion and differentiation of malignant TFH-cells (66). The gene discussed is IDH2; the disease is angioimmunoblastic T-cell lymphoma.